CN113226304A - 免疫抑制药物组合物及其应用 - Google Patents

免疫抑制药物组合物及其应用 Download PDF

Info

Publication number
CN113226304A
CN113226304A CN201980087113.0A CN201980087113A CN113226304A CN 113226304 A CN113226304 A CN 113226304A CN 201980087113 A CN201980087113 A CN 201980087113A CN 113226304 A CN113226304 A CN 113226304A
Authority
CN
China
Prior art keywords
forskolin
coch
compound
pharmaceutical composition
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980087113.0A
Other languages
English (en)
Other versions
CN113226304B (zh
Inventor
巩晓明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Ming Jun Biological Technology Co ltd
Original Assignee
Shanghai Ming Jun Biological Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Ming Jun Biological Technology Co ltd filed Critical Shanghai Ming Jun Biological Technology Co ltd
Publication of CN113226304A publication Critical patent/CN113226304A/zh
Application granted granted Critical
Publication of CN113226304B publication Critical patent/CN113226304B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

提供了用于进行免疫抑制如治疗银屑病等的包括福司可林衍生物或其盐以及任选地前列腺素类化合物或糖皮质激素类化合物的药物、药物组合物、或药物试剂盒。还提供了进行免疫抑制的方法，其包括以福司可林衍生物或其盐以及任选地前列腺素类化合物或糖皮质激素类化合物给药。福司可林衍生物在单独或联合用药时有望成为用于免疫抑制如治疗银屑病的一类新机制小分子药物，相较一线抗体用药有显著工艺和价格优势，与临床一线化药卡泊三醇倍他米松软膏相比疗效相当、副作用更少。

Description

PCT国内申请，说明书已公开。

Claims (82)

  1. PCT国内申请，权利要求书已公开。
CN201980087113.0A 2018-12-29 2019-12-30 免疫抑制药物组合物及其应用 Active CN113226304B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811645299 2018-12-29
CN2018116452990 2018-12-29
PCT/CN2019/129945 WO2020135872A1 (zh) 2018-12-29 2019-12-30 免疫抑制药物组合物及其应用

Publications (2)

Publication Number Publication Date
CN113226304A true CN113226304A (zh) 2021-08-06
CN113226304B CN113226304B (zh) 2023-03-24

Family

ID=71127508

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980087113.0A Active CN113226304B (zh) 2018-12-29 2019-12-30 免疫抑制药物组合物及其应用

Country Status (6)

Country Link
US (1) US20220079915A1 (zh)
EP (1) EP3903778A4 (zh)
CN (1) CN113226304B (zh)
AU (1) AU2019414693A1 (zh)
CA (1) CA3125226C (zh)
WO (1) WO2020135872A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2749360C1 (ru) * 2020-10-09 2021-06-09 Федеральное государственное бюджетное военное образовательное учреждение высшего образования "Военно-медицинская академия имени С.М. Кирова" Министерства обороны Российской Федерации (ВМедА) Способ лечения ладонно-подошвенного пустулеза

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2235678A1 (en) * 1973-07-02 1975-01-31 Merck & Co Inc Topical antipsoriasis agents - contg. prostaglandin E1 or E2
WO1985003637A1 (en) * 1984-02-24 1985-08-29 Halprin Kenneth M Methods and pharmaceutical compositions for the treatment of hyperplastic diseases of the skin
CN1058403A (zh) * 1990-07-24 1992-02-05 赫彻斯特股份公司 制备福司可林的6-(取代氨基丙酰基)衍生物的方法
US5789439A (en) * 1990-03-23 1998-08-04 Nippon Kayaku Kabushiki Kaisha Pharmaceutical use of forskolin derivatives
US20060233743A1 (en) * 2002-10-21 2006-10-19 Kelly Rodney W Compositions and methods of therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU591196B2 (en) 1985-11-15 1989-11-30 Nippon Kayaku Kabushiki Kaisha Novel forskolin derivatives
US4883793A (en) * 1988-05-09 1989-11-28 Hoechst-Roussel Pharmaceuticals Inc. Hydrazinocarbonyloxylabdanes for treating cardiac failure
JP2010186084A (ja) 2009-02-12 2010-08-26 Brother Ind Ltd 情報表示装置及び情報表示用プログラム

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2235678A1 (en) * 1973-07-02 1975-01-31 Merck & Co Inc Topical antipsoriasis agents - contg. prostaglandin E1 or E2
WO1985003637A1 (en) * 1984-02-24 1985-08-29 Halprin Kenneth M Methods and pharmaceutical compositions for the treatment of hyperplastic diseases of the skin
US5789439A (en) * 1990-03-23 1998-08-04 Nippon Kayaku Kabushiki Kaisha Pharmaceutical use of forskolin derivatives
CN1058403A (zh) * 1990-07-24 1992-02-05 赫彻斯特股份公司 制备福司可林的6-(取代氨基丙酰基)衍生物的方法
US20060233743A1 (en) * 2002-10-21 2006-10-19 Kelly Rodney W Compositions and methods of therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
黄英举等: "银屑病治疗研究新进展", 《中国医学创新》 *

Also Published As

Publication number Publication date
CN113226304B (zh) 2023-03-24
EP3903778A1 (en) 2021-11-03
CA3125226A1 (en) 2020-07-02
AU2019414693A1 (en) 2021-08-12
CA3125226C (en) 2023-10-10
US20220079915A1 (en) 2022-03-17
WO2020135872A1 (zh) 2020-07-02
EP3903778A4 (en) 2022-09-07

Similar Documents

Publication Publication Date Title
RU2671488C2 (ru) Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака
KR20200105731A (ko) 포르볼 에스테르의 조성물
CN116549437A (zh) 大麻素类和n-酰基乙醇胺的组合
US12029772B2 (en) Willow extract and its use in treating a viral infection, allergic reaction, and other medical conditions
NZ603874A (en) Oral dosage forms of bendamustine and therapeutic use thereof
US10172876B2 (en) Use of ginsenoside M1 for treating IgA nephropathy
CN101801386A (zh) 抗血管生成剂和使用方法
TWI836022B (zh) 治療纖維化之方法
CN113226304B (zh) 免疫抑制药物组合物及其应用
EP3518936A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
AU2017272889B2 (en) Combination therapy comprising a polyunsaturated ketone and a calcineurin inhibitor
EP4218758A2 (en) Glutarimide derivative for overcoming resistance to steriods
Lordan et al. H1-antihistamines in asthma
EP2808025B1 (en) Pharmaceutical composition and quasi-drug cosmetic using same
US20230248671A1 (en) Use of beta-1 adrenergic receptor antagonist for preparing compositions for reducing epithelial cell damage induced by epidermal growth factor receptor inhibitors and inhibiting cancer cells
KR101470087B1 (ko) 면역억제제 및 트랜스글루타미나제 ２ 억제제를 포함하는 아토피 피부염의 예방, 치료 또는 개선용 조성물
JP6202339B2 (ja) ＧＭ−ＣＳＦ産生Ｔ細胞制御剤、及びＴｈ１／Ｔｈ２免疫バランス調節剤
JP2023529365A (ja) 骨髄増殖性腫瘍の治療のための、ルキソリチニブとｉｎｃｂ０５７６４３との組合わせ
KR20190134825A (ko) 수축력 저하 수반성 배뇨근 과활동 개선제
AU2005283829A1 (en) Pindolol for the treating premenstrual syndrome and premenstrual dysphoric disorder
US20160106698A9 (en) Compositions And Methods Of Use Of Phorbol Esters
Samoliński et al. Intranasal combo: fixed-dose combination of mometasone furoate and olopatadine hydrochloride in therapeutic strategies for rhinosinusitis
CN115381818A (zh) 一种促进细胞自噬降解功能的方法及应用
KR20210015849A (ko) 트로피펙소르 및 세니크리비록을 포함하는 조합물
CN112274511A (zh) 用于治疗移植物抗宿主病的喹啉衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant